Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,342.81
    -27.71 (-0.05%)
     

  • CMC Crypto 200

    1,368.41
    +55.79 (+4.25%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Astra looking to partner or sell infection, neuroscience drugs

Reuters - UK Focus

LONDON, April 24 (Reuters) - AstraZeneca (NYSE: AZN - news) is looking to partner or sell its anti-infective and neuroscience drugs, since these products are no longer core areas for the British drugmaker, its chief executive said on Thursday.

Pascal Soriot told reporters in a first-quarter conference call that he was investigating all options for the businesses as the drugmaker redeploys resources to the priority areas of oncology, cardiovascular and metabolic diseases, and respiratory and inflammation.

(Reporting by Ben Hirschler; Editing by Mark Potter)